As positive results were observed in prior research on LR-MDS patients who did not have RS or SF3B1 mutations, the COMMANDS phase III trial [20] expanded luspatercept use to all LR-MDS patients regardless of RS or SF3B1 status. Here, SF3B1 is linked to myelodysplastic syndrome.